Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza

医学 核酸内切酶 酶抑制剂 药理学 病毒学 酶 生物化学 化学
作者
Tianrui Yang
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:53 (7): 754-759 被引量:57
标识
DOI:10.1177/1060028019826565
摘要

Objective: To review the pharmacology, pharmacokinetics, clinical trials, and clinical implications of baloxavir marboxil. Data Sources: A MEDLINE search was conducted using the terms baloxavir, baloxavir marboxil, cap-dependent endonuclease inhibitor, and polymerase acidic endonuclease inhibitor. Additional data were obtained from the prescribing information and relevant guidelines. Study Selection and Data Extraction: All clinical trials were included. Data Synthesis: Baloxavir marboxil exploits a new mechanism of action of inhibiting cap-dependent endonuclease. Baloxavir was shown to be superior compared with placebo and noninferior compared with oseltamivir with regard to the primary end point. Baloxavir was well tolerated in the trials. A second phase III study investigating high-risk patients was completed with positive results. However, the full article is not yet published. Relevance to Patient Care and Clinical Practice: The small amount of literature limits baloxavir’s use in certain patient populations. Baloxavir offers advantages such as single-dose regimen, eliminating adherence concerns and lack of cross-resistance, making it an alternative for resistant viruses. Several uncertainties remain. Baloxavir has not been studied in hospitalized patients, patients with symptoms for >48 hours, or in combination with other antiviral agents. Furthermore, resistance to baloxavir can develop after 1 dose. Clinical studies are ongoing to evaluate baloxavir in young pediatric patients, hospitalized patients, and in combination therapy with neuraminidase inhibitors to further elucidate baloxavir’s place in therapy. Conclusion: Baloxavir is a new antiviral medication for the treatment of influenza. Given the new mechanism of action, baloxavir may be useful in treating patients with resistant viruses.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
打打的应助被xixi采纳,获得20
1秒前
小青发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
2秒前
2秒前
Akim的应助被忧子忘采纳,获得10
2秒前
可可酱完成签到,获得积分10
2秒前
zhong完成签到,获得积分10
3秒前
3秒前
木木兮完成签到 ,获得积分10
3秒前
Ava的应助被kk采纳,获得10
3秒前
3秒前
汉堡包的应助被我是微风采纳,获得10
3秒前
4秒前
xjh的应助被辛勤诗兰采纳,获得30
4秒前
4秒前
月下荷花完成签到 ,获得积分10
5秒前
常芹完成签到,获得积分10
5秒前
163完成签到 ,获得积分10
5秒前
6秒前
蓝天的应助被nn采纳,获得10
7秒前
7秒前
赵琪完成签到,获得积分10
7秒前
老橡树发布了新的文献求助20
7秒前
llj发布了新的文献求助10
7秒前
Bugs完成签到,获得积分10
8秒前
8秒前
桔子鲁完成签到,获得积分10
8秒前
8秒前
微微发布了新的文献求助10
8秒前
yu关闭了yu的文献求助
9秒前
Luu完成签到 ,获得积分10
9秒前
9秒前
可可完成签到 ,获得积分10
9秒前
仁爱的怜南完成签到,获得积分10
9秒前
可爱的函函的应助被chen采纳,获得10
9秒前
怡然听兰完成签到,获得积分10
10秒前
华仔的应助被xhy采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153442
求助须知:如何正确求助?哪些是违规求助? 9550127
关于积分的说明 21696715
捐赠科研通 7741908
什么是DOI,文献DOI怎么找? 3425483
关于科研通互助平台的介绍 2550608
邀请新用户注册赠送积分活动 2469152